Gujarat Kidney And Super Speciality DuPont analysis

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
0.81×0.79×
0.96×0.95×
21.3%27.1%
0.28×0.28×
1.17×1.17×
5.4%6.7%
6.1%6.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GKSL₹171.87

Gujarat Kidney And Super Speciality Limited

· Pharma & Health
₹ CrorePeersGPTHEALTHSHALBYINDRAMEDCOLOTUSEYEARTEMISMEDDRAGARWQKMCSHILKOVAIMcap ₹1,355 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.790.81
Interest Burden (Pretax/EBIT) ×0.950.96
EBIT Margin %27.1221.30
Asset Turnover ×0.280.28
Financial Leverage (Assets/Equity) ×1.171.17
ROE (5-step product, year-end total equity) %6.715.42
ROE (owners' profit / average owners' equity) %6.146.14
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.